Neupro for Restless Legs Syndrome

UCB Pharma has launched two new strengths of Neupro (rotigotine) transdermal patches 1mg/24hr and 3mg/24hr. These additional strengths can be used alongside the existing 2mg/24hr patch in the management of moderate to severe idiopathic restless legs syndrome.

Treatment should be initiated using a 1mg/24hr patch daily and increased according to patient response in weekly increments of 1mg/24hr until an effective dose is reached or the maximal dose of 3mg/24hr is reached.

The need for treatment continuation should be reconsidered every six months.

The mechanism of action for rotigotine in restless legs syndrome is not fully understood.

View Neupro drug record

Further information: UCB Pharma

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more